KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

Cited by (882)

Items 101–200 of 882

1. Precision medicine review: rare driver mutations and their biophysical classification
   Ruth Nussinov, Hyunbum Jang, Chung‐Jung Tsai, Feixiong Cheng · 2019 · Biophysical Reviews
2. A massively parallel infrastructure for adaptive multiscale simulations
   Francesco Di Natale, Harsh Bhatia, Timothy S. Carpenter, Chris Neale, Sara I. L. Kokkila-Schumacher, Tomas Oppelstrup, Liam G. Stanton, Xiaohua Zhang, Shiv Sundram, Tom Scogland et al. · 2019 · International Conference for High Performance Computing, Networking, Storage and Analysis (SC)
3. Homeodomain‐interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer
   Yi Qin, Qiangsheng Hu, Shunrong Ji, Jin Xu, Weixing Dai, Wensheng Liu, Wenyan Xu, Qiqing Sun, Zheng Zhang, Quanxing Ni et al. · 2019 · Cell Proliferation
4. Dietary Energy Modulation and Autophagy: Exploiting Metabolic Vulnerabilities to Starve Cancer
   Alyssa Joy Cozzo, Michael F. Coleman, Jane B. Pearce, Alexander J. Pfeil, Suhas K. Etigunta, Stephen David Hursting · 2020 · Frontiers in Cell and Developmental Biology
5. Pancreatic Cancer and Its Microenvironment—Recent Advances and Current Controversies
   Kinga B. Stopa, Agnieszka A. Kusiak, Mateusz D. Szopa, Paweł E. Ferdek, Monika A. Jakubowska · 2020 · International Journal of Molecular Sciences
6. Multifaceted role for p53 in pancreatic cancer suppression
   Mello, Stephano S., Flowers, Brittany M., Mazur, Pawel K., Lee, James J., Müller, Fabian, Denny, Sarah K., Ferreira, Sofia, Hanson, Kathryn, Kim, Seung K., Greenleaf, William J. et al. · 2023 · Proceedings of the National Academy of Sciences
7. Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer
   Marta Toledano‐Fonseca, María Teresa Cano, Elizabeth Inga, Rosa María Rodríguez-Alonso, María Auxiliadora Gómez‐España, Silvia Guil‐Luna, Rafael Mena‐Osuna, Juan de la Haba-Rodríguez, Antonio Rodríguez‐Ariza, Enrique Aranda · 2020 · Cancers
8. The CD44/COL17A1 pathway promotes the formation of multilayered, transformed epithelia
   Kei Kozawa, Miho Sekai, Kenji Ohba, Shoko Ito, Hiroaki Sako, Takeshi Maruyama, Mai Kakeno, Takanobu Shirai, Keisuke Kuromiya, Tomoko Kamasaki et al. · 2021 · Current Biology
9. Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment
   Rakesh Bhatia, Namita Bhyravbhatla, Andrew Kisling, Xiaoqi Li, Surinder K. Batra, Sushil Kumar K · 2022 · Seminars in Cancer Biology
10. Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer
    Dongfeng Qu, Nathaniel Weygant, Jiannan Yao, Parthasarathy Chandrakesan, William L. Berry, Randal J. May, Kamille Pitts, Sanam Husain, Stan A. Lightfoot, Min Li et al. · 2019 · Journal of Oncology
11. Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets
    Alexandros Karagiannakos, Maria Adamaki, Antonis Tsintarakis, Bořivoj Vojtěšek, Robin Fåhræus, Vassilis C. Zoumpourlis, Konstantinos Karakostis · 2022 · Cancers
12. Curing pancreatic cancer
    Benno Traub, K.H. Link, Marko Kornmann · 2021 · Seminars in Cancer Biology
13. Liquid biopsy in pancreatic cancer – Current perspective and future outlook
    Yaru Zhao, Jiajia Tang, Ke Jiang, Shin-Yi Liu, Alexandra Aicher, Christopher Heeschen · 2023 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
14. Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging
    Bezukladova, Svetlana, Tuisku, Jouni, Matilainen, Markus, Vuorimaa, Anna, Nylund, Marjo, Smith, Sarah, Sucksdorff, Marcus, Mohammadian, Mehrbod, Saunavaara, Virva, Laaksonen, Sini et al. · 2020 · Neurology Neuroimmunology & Neuroinflammation
15. PDAC, the Influencer Cancer: Cross-Talk with Tumor Microenvironment and Connected Potential Therapy Strategies
    Leonardo Mercanti, Maria Sindaco, Mariangela Mazzone, Maria Carmela Di Marcantonio, Mariagrazia Piscione, Raffaella Muraro, Gabriella Mincione · 2023 · Cancers
16. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer
    Deniz Can Güven, Taha Koray Şahin, Hasan Çagri Yildirim, Oktay Halit Aktepe, Ömer Dızdar, Şuayib Yalçın · 2021 · Critical Reviews in Oncology/Hematology
17. The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix
    Xuan Pei, Libing Xiang, Wei Chen, Wei Jiang, Lina Yin, Xuxia Shen, Xiaoyan Zhou, Huijuan Yang · 2021 · Gynecologic Oncology
18. KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin
    Wen-Hsuan Chang, Thuy‐Tien T. Nguyen, Chia‐Hsin Hsu, Kirsten L. Bryant, Hong Jin Kim, Haoqiang Ying, Jon W. Erickson, Channing J. Der, Richard A. Cerione, Marc A. Antonyak · 2021 · Cancer Letters
19. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis
    Wenjie Ge, Algera Goga, Yuliang He, Pamuditha N. Silva, Christian Hirt, Karolin Herrmanns, Ilaria Guccini, Svenja Godbersen, Gerald Schwank, Markus Stoffel · 2021 · Gastroenterology
20. Extracellular vesicles are the primary source of blood‐borne tumour‐derived mutant KRAS DNA early in pancreatic cancer
    Daniel W. Hagey, Maximilian Kordes, André Görgens, Metoboroghene Oluwaseyi Mowoe, Joel Z. Nordin, Carlos Fernández Moro, Matthias J. Löhr, Samir EL Andaloussi · 2021 · Journal of Extracellular Vesicles
21. MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition
    Mark R. Silvis, Dilru Silva, Riley Rohweder, Sophia S. Schuman, Swapna Aravind Gudipaty, Amanda Truong, Jeffrey T. Yap, Kajsa E. Affolter, Martin McMahon, Conan Grant Kinsey · 2022 · The Journal of Experimental Medicine
22. The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma
    Faria Nusrat, Akshay Khanna, Aditi Jain, Wei Jiang, Harish Lavu, Charles J. Yeo, Wilbur Bo Bowne, Avinoam Nevler · 2024 · Journal of Clinical Medicine
23. Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function
    Walaa E. Kattan, Wei Chen, Xiaoping Ma, Tien-Hung Lan, Dharini van der Hoeven, Ransome van der Hoeven, John F. Hancock · 2019 · Life Science Alliance
24. Exploiting macropinocytosis for drug delivery into KRAS mutant cancer
    Huiqin Liu, Feng Qian · 2022 · Theranostics
25. Functional and biological heterogeneity of KRAS Q61 mutations
    Minh V. Huynh, G. Aaron Hobbs, Antje Schaefer, Mariaelena Pierobon, Leiah M. Carey, J. Nathaniel Diehl, Jonathan M. DeLiberty, Ryan D. Thurman, Adelaide R. Cooke, Craig M. Goodwin et al. · 2022 · Science Signaling
26. Oligomeric organization of membrane proteins from native membranes at nanoscale spatial and single-molecule resolution
    Gerard Walker, Caroline Brown, Xiangyu Ge, Shailesh Kumar, Mandar Deepak Muzumdar, Kallol Gupta, Moitrayee Bhattacharyya · 2023 · Nature Nanotechnology
27. Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
    Panagiotis Filis, Dimitrios Salgkamis, Alexios Matikas, Ioannis Zerdes · 2024 · Drug Discovery Today
28. An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness
    Meiyu Quan, Qiang Guo, Jiayu Liu, Ruo Yang, Jing Bai, Wei Wang, Yaxin Cai, Rui Han, Yu-Qing Lv, Li Ding et al. · 2020 · Frontiers in Cell and Developmental Biology
29. Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer
    Walaa E. Kattan, Junchen Liu, Dina Montufar‐Solis, Liang Hong, Bhargavi Brahmendra Barathi, Ransome van der Hoeven, Yong Zhou, John F. Hancock · 2021 · Proceedings of the National Academy of Sciences
30. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
    Heng‐Chung Kung, Jun Yu · 2023 · MedComm
31. Targeting the RAS upstream and downstream signaling pathway for cancer treatment
    Md. Arafat Hossain · 2024 · European Journal of Pharmacology
32. Next-Generation Sequencing in Pancreatic Cancer
    Gong-Qing Shen, Essa M. Aleassa, Richard Matthew Walsh, Gareth J Morris‐Stiff · 2019 · Pancreas
33. Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer
    Sohinee Bhattacharyya, Chet Huan Oon, Aayush Kothari, Wesley R. Horton, Jason M. Link, Rosalie C. Sears, Mara H. Sherman · 2020 · The Journal of Experimental Medicine
34. Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
    Enrique Rozengurt, Guido Eibl · 2026 · Signal Transduction and Targeted Therapy
35. Pancreatic cancer stem cells: Perspectives on potential therapeutic approaches of pancreatic ductal adenocarcinoma
    Claudia Di Carlo, Jessica Brandi, Daniela Cecconi · 2018 · World Journal of Stem Cells
36. Discovery of the 3-Amino-1,2,4-triazine-Based Library as Selective PDK1 Inhibitors with Therapeutic Potential in Highly Aggressive Pancreatic Ductal Adenocarcinoma
    Daniela Carbone, Michele De Franco, Camilla Pecoraro, Davide Bassani, Matteo Pavan, Stella Cascioferro, Barbara Parrino, Girolamo Cirrincione, Stefano Dall’Acqua, Stefano Moro et al. · 2023 · International Journal of Molecular Sciences
37. Targeting mutated GTPase KRAS in tumor therapies
    Guangjin Fan, Linlin Lou, Zhendong Song, Xiaolei Zhang, Xiao‐Feng Xiong · 2021 · European Journal of Medicinal Chemistry
38. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment
    Jennifer E. Klomp, Ye S. Lee, Craig M. Goodwin, Bjoern Papke, Jeffrey A. Klomp, Andrew M. Waters, Clint A. Stalnecker, Jonathan M. DeLiberty, Kristina Drizyte‐Miller, Runying Y. Yang et al. · 2021 · Cell Reports
39. Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
    Singh, Kamini, Lin, Jianan, Lecomte, Nicolas, Mohan, Prathibha, Gokce, Askan, Sanghvi, Viraj R., Jiang, Man, Grbovic-Huezo, Olivera, Burčul, Antonija, Stark, Stefan G. et al. · 2021 · Cancer Research
40. A Systematic Review of Resting-State Functional MRI Connectivity Changes and Cognitive Impairment in Multiple Sclerosis
    Danka Jandric, Anisha Doshi, Richelle Scott, David Paling, David J. Rog, Jeremy Chataway, Menno Michiel Schoonheim, Geoff J.M. Parker, Nils Muhlert · 2021 · Brain Connectivity
41. Sesquiterpene Lactones as Promising Candidates for Cancer Therapy: Focus on Pancreatic Cancer
    Laura Cecilia Laurella, Nadia Talin Mirakian, María Noé Garcia, Daniel Grasso, Valeria Patricia Sülsen, Daniela Laura Papademetrio · 2022 · Molecules
42. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives
    Christos Adamopoulos, Donatella Delle Cave, Athanasios G. Papavassiliou · 2024 · International Journal of Molecular Sciences
43. Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management
    Nikhil Gupta, Raghav Yelamanchi · 2021 · World Journal of Gastroenterology
44. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
    Oihane Erice, Shruthi Narayanan, Iker Feliu, Rodrigo Entrialgo‐Cadierno, Antonia Malinova, Caterina Vicentini, Elizabeth Guruceaga, Pietro Delfino, Marija Trajkovic‐Arsic, Haritz Moreno et al. · 2023 · Clinical Cancer Research
45. An ERK1/2‐driven RNA‐binding switch in nucleolin drives ribosome biogenesis and pancreatic tumorigenesis downstream of RAS oncogene
    Muhammad S. Azman, Emilie L. Alard, Martin Dodel, Federica Capraro, Rupert Faraway, Maria Dermit, Wanling Fan, Alina Chakraborty, Jernej Ule, Faraz K. Mardakheh · 2023 · The EMBO Journal
46. Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology
    Bryony J. Telford, Sanaz Yahyanejad, Thijs de Gunst, Harm C. den Boer, Rogier M. Vos, Marieke Stegink, Marion T.J. van den Bosch, Mir Farshid Alemdehy, Laurens A.H. van Pinxteren, Roel Q.J. Schaapveld et al. · 2021 · Oncotarget
47. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
    Patrick M. Grierson, Benjamin R. Tan, Katrina Sophia Pedersen, Haeseong Park, Rama Suresh, Manik A. Amin, Nikolaos A. Trikalinos, Deborah L. Knoerzer, Brent L. Kreider, Anupama Reddy et al. · 2022 · The Oncologist
48. Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer
    Frank, Katrin J., Mulero-Sánchez, Antonio, Berninger, Alexandra, Ruiz-Cañas, Laura, Bosma, Astrid, Görgülü, Kıvanç, Wu, Nan, Diakopoulos, Kalliope N., Kaya-Aksoy, Ezgi, Ruess, Dietrich A. et al. · 2022 · Cell Reports Medicine
49. Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice
    Bhairavi Tolani, Anna Celli, Yanmin Yao, Yong Zi Tan, Richard Doty Fetter, Christina R. Liem, Adam J. de Smith, Thamiya Vasanthakumar, Paola Bisignano, Adam D. Cotton et al. · 2022 · Nature Biotechnology
50. Biomimetic Gold Nanorods Modified with Erythrocyte Membranes for Imaging-Guided Photothermal/Gene Synergistic Therapy
    Kai Guo, Shuai Ren, Huifeng Zhang, Yingying Cao, Yatong Zhao, Yajie Wang, Wenli Qiu, Ying Tian, Lina Song, Zhongqiu Wang · 2023 · ACS Applied Materials & Interfaces
51. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer
    Corina E. Antal, Tae Gyu Oh, Stefan Aigner, En‐Ching Luo, Brian A. Yee, Tania Campos, Hervé Tiriac, Katherine L. Rothamel, Cheng Zhang, Henry Jiao et al. · 2023 · Nature Communications
52. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers
    Alexander J. Cammack, Nazem Atassi, Theodore S. Hyman, Leonard H. van den Berg, Matthew B. Harms, Robert H. Baloh, Robert H. Brown, Michael A. van Es, Jan Herman Veldink, Bálint S. de Vries et al. · 2019 · Neurology
53. Macropinocytosis and Cancer: From Tumor Stress to Signaling Pathways
    Guillem Lambies, Cosimo Commisso · 2022 · Sub-cellular biochemistry/Subcellular biochemistry
54. Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma
    Mengni He, Mackenzie Henderson, Stephen Muth, A. Murphy, Lei Zheng · 2020 · Annals of Pancreatic Cancer
55. Persistent ferroptosis promotes cervical squamous intraepithelial lesion development and oncogenesis by regulating KRAS expression in patients with high risk-HPV infection
    Tianming Wang, Min Gong, Yuting Cao, Chengcheng Zhao, Yingfei Lu, Yu Zhou, Shasha Yao, Jianquan Chen, Chun Ling Zhao, Rong Ju · 2022 · Cell Death Discovery
56. Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
    Emily Nicole Arner, Wenting Du, Rolf A. Brekken · 2019 · Frontiers in Oncology
57. Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification
    Pilar Espiau-Romera, Sarah Courtois, Beatriz Parejo-Alonso, Patricia Sancho · 2020 · Journal of Clinical Medicine
58. Machine-learning-based dynamic-importance sampling for adaptive multiscale simulations
    Harsh Bhatia, Timothy S. Carpenter, Helgi I. Ingólfsson, Gautham Dharuman, Piyush Karande, Shusen Liu, Tomas Oppelstrup, Chris Neale, Felice C. Lightstone, Brian Van Essen et al. · 2021 · Nature Machine Intelligence
59. FcRn expression in cancer: Mechanistic basis and therapeutic opportunities
    Imke Rudnik‐Jansen, Kenneth Alan Howard · 2021 · Journal of Controlled Release
60. Identification of treatment‐induced vulnerabilities in pancreatic cancer patients using functional model systems
    Katja Peschke, Hannah Jakubowsky, Arlett Schäfer, H. Carlo Maurer, Sebastian Lange, Felix Orben, Raquel Bernad, Felix N Harder, Matthias Eiber, Rupert Öllinger et al. · 2022 · EMBO Molecular Medicine
61. Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target
    Josef Gillson, Yomna S. Abd El-Aziz, Lionel Yi Wen Leck, Patric J. Jansson, Nick Pavlakis, Jaswinder Singh Samra, Anubhav Mittal, Sumit Sahni · 2022 · Cancers
62. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
    Gu, Meichen, Gao, Yanli, Chang, Pengyu · 2021 · Cancers
63. The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
    Firas Batrash, Mahmoud Kutmah, Jun Zhang · 2023 · Experimental Hematology and Oncology
64. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer
    Ashenafi Shiferaw Bulle, Peng Liu, Kuljeet Seehra, Sapana Bansod, Yali Chen, Kiran Zahra, Vikas Somani, Iftikhar Ali Khawar, Hung-Po Chen, Paarth B. Dodhiawala et al. · 2024 · Nature Communications
65. Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC)
    Alessandro Gregori, Cecilia Bergonzini, Mjriam Capula, Giulia Mantini, Fatemeh Khojasteh‐Leylakoohi, Annalisa Comandatore, Ghazaleh Khalili‐Tanha, Alireza Tabib khooei, Luca Morelli, Amir Avan et al. · 2023 · Cancers
66. Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells
    Shuai Han, Xin Li, Yun Xia, Zhengsen Yu, Ningning Cai, Satish R. Malwal, Xu Han, Eric Oldfield, Yonghui Zhang · 2019 · Journal of Medicinal Chemistry
67. Oncogene-Induced Senescence Limits the Progression of Pancreatic Neoplasia through Production of Activin A
    Yajie Zhao, Zhichong Wu, Marie Chanal, Fabienne Guillaumond, Delphine Goehrig, Sophie Bachy, Moitza Principe, Audrey Ziverec, Jean‐Michel Flaman, Guillaume Collin et al. · 2020 · Cancer Research
68. The Combination of Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer
    Marta Toledano‐Fonseca, María Teresa Cano, Elizabeth Inga, Auxiliadora Gómez‐España, Silvia Guil‐Luna, Maria Victoria García‐Ortiz, Rafael Mena‐Osuna, Juan de la Haba-Rodríguez, Antonio Rodríguez‐Ariza, Enrique Aranda · 2021 · Cancers
69. Facile one-step synthesis of NIR-Responsive siRNA-Inorganic hybrid nanoplatform for imaging-guided photothermal and gene synergistic therapy
    Xiuna Jia, Mengmeng Lv, Yunwei Fei, Qingfeng Dong, Hao Wang, Qiong Liu, Dan Li, Jin Wang, Erkang Wang · 2022 · Biomaterials
70. Matairesinol Induces Mitochondrial Dysfunction and Exerts Synergistic Anticancer Effects with 5-Fluorouracil in Pancreatic Cancer Cells
    Woonghee Lee, Gwonhwa Song, Hyocheol Bae · 2022 · Marine Drugs
71. TP53 Gain-of-Function and Non–Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma
    Minggui Pan, Chen Jiang, Zheyang Zhang, Ninah S. Achacoso, Stacey Alexeeff, Aleyda V. Solorzano, Pam Tse, Elaine H. Chung, Tilak Kumar Sundaresan, Jennifer Marie Suga et al. · 2023 · JCO Precision Oncology
72. PLA2G2A Phospholipase Promotes Fatty Acid Synthesis and Energy Metabolism in Pancreatic Cancer Cells with K-ras Mutation
    Mingquan Zhang, Rong Xiang, Christophe Glorieux, Peng Huang · 2022 · International Journal of Molecular Sciences
73. Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
    Friederike Inga Nollmann, Dietrich Alexander Ruess · 2020 · Biomedicines
74. Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation
    Rongqin Ren, Somashekar Gopala Krishna, Wei Chen, Wendy L. Frankel, Rulong Z. Shen, Weiqiang Zhao, Matthew R. Avenarius, Jason P. Garee, Sean Caruthers, Dan M. Jones · 2020 · Modern Pathology
75. REG3A/REG3B promotes acinar to ductal metaplasia through binding to EXTL3 and activating the RAS-RAF-MEK-ERK signaling pathway
    Huairong Zhang, Andrea Liliam Gomez Corredor, Julia Messina‐Pacheco, Qing Li, George Zogopoulos, Nancy Kaddour, Yifan Wang, Bingyin Shi, Alex Gregorieff, Jun‐Li Liu et al. · 2021 · Communications Biology
76. Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer
    Principe, Daniel R., Underwood, Patrick W., Kumar, Sandeep, Timbers, Kaytlin E., Koch, Regina M., Trevino, Jose G., Munshi, Hidayatullah G., Rana, Ajay · 2022 · Frontiers in Oncology
77. <i>KRAS</i> Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas
    Diehl, Adam C, Hannan, Lindsay M, Zhen, David B, Coveler, Andrew L, King, Gentry, Cohen, Stacey A, Harris, William P, Shankaran, Veena, Wong, Kit M, Green, Steven et al. · 2022 · The Oncologist
78. Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy
    Yukai Huang, Wei‐Chung Cheng, Ting-Ting Kuo, Juan‐Cheng Yang, Yang‐Chang Wu, Heng‐Hsiung Wu, Chia-Chien Lo, Chih-Ying Hsieh, Sze‐Ching Wong, Chih‐Hao Lu et al. · 2024 · Nature Cancer
79. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method
    Michael Haas, Dirk Waldschmidt, Michael Ståhl, A. C. Reinacher-Schick, Jens Freiberg‐Richter, Ludwig Fischer von Weikersthal, F. Kaiser, Stefan Kanzler, Norbert Frickhofen, Thomas Theodor Werner Seufferlein et al. · 2021 · European Journal of Cancer
80. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition
    Andrew M. Waters, Tala O. Khatib, Bjoern Papke, Craig M. Goodwin, G. Aaron Hobbs, J. Nathaniel Diehl, Runying Y. Yang, A. Cole Edwards, Katherine H. Walsh, Rita Sulahian et al. · 2021 · Cell Reports
81. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers
    Pandey, Divya, Chauhan, Subhash C., Kashyap, Vivek K., Roy, Kuldeep K. · 2024 · European Journal of Medicinal Chemistry
82. Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas
    Piera Zaccari, Vincenzo Cardinale, Carola Severi, Federica Pedica, Guido Carpino, Eugenio Gaudio, Claudio Doglioni, Maria Chiara Petrone, Domenico Alvaro, Paolo Giorgio Arcidiacono et al. · 2019 · World Journal of Gastroenterology
83. The Role of Autophagy in Pancreatic Cancer—Recent Advances
    Maria I. New, Sharon A. Tooze · 2019 · Biology
84. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations
    Paarth B. Dodhiawala, Namrata Khurana, Daoxiang Zhang, Yi Cheng, Lin Li, Qing Wei, Kuljeet Seehra, Hongmei Jiang, Patrick M. Grierson, Andrea Wang‐Gillam et al. · 2020 · Journal of Clinical Investigation
85. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo
    Zhang, Yuchen, Li, Cheukfai, Xia, Chenglai, Wah To, Keneth Kin, Guo, Zhixing, Ren, Chongyang, Wen, Lingzhu, Wang, Fang, Fu, Liwu, Liao, Ning · 2022 · Cell Communication and Signaling
86. PHLPPing the Script: Emerging Roles of PHLPP Phosphatases in Cell Signaling
    Timothy R. Baffi, Ksenya Cohen‐Katsenelson, Alexandra C. Newton · 2020 · The Annual Review of Pharmacology and Toxicology
87. Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
    Rong Du, Delaney K. Sullivan, Nancy G. Azizian, Yuanhui Liu, Yulin Li · 2021 · BMC Cancer
88. Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting
    Annalisa Pappalardo, Emilio Francesco Giunta, Giuseppe Tirino, Luca Pompella, Piera Federico, Bruno Daniele, Ferdinando De Vita, Angelica Petrillo · 2021 · Frontiers in Oncology
89. The Role of Smoothened-Dependent and -Independent Hedgehog Signaling Pathway in Tumorigenesis
    Jian Yi Chai, Vaisnevee Sugumar, Mohammed Abdullah Alshawsh, Won Fen Wong, Aditya Arya, Pei Pei Chong, Chung Yeng Looi · 2021 · Biomedicines
90. Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next‐generation sequencing acquired by endoscopic ultrasound–guided FNA and FNB
    Qiong Gan, Sinchita Roy‐Chowdhuri, Dzifa Y. Duose, John Stewart, Emmanuel S. Coronel, Manoop S. Bhutani, Jeffrey H. Lee, Brian R. Weston, Phillip S. Ge, William A. Ross et al. · 2021 · Cancer Cytopathology
91. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status
    Brianna R. Daley, Heidi M. Vieira, Chaitra Rao, Jacob M. Hughes, Zaria Beckley, Dianna H. Huisman, Deepan Chatterjee, Nancy E. Sealover, Katherine Cox, James W. Askew et al. · 2023 · Proceedings of the National Academy of Sciences
92. Role of Tumor and Stroma-Derived IGF/IGFBPs in Pancreatic Cancer
    Divya Thomas, Prakash Radhakrishnan · 2020 · Cancers
93. RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics
    Walaa E. Kattan, John F. Hancock · 2020 · Biochemical Journal
94. Identifying MMP14 and COL12A1 as a potential combination of prognostic biomarkers in pancreatic ductal adenocarcinoma using integrated bioinformatics analysis
    Jingyi Ding, Yanxi Liu, Yu Lai · 2020 · PeerJ
95. Macroautophagy/autophagy promotes resistance to KRASG12D-targeted therapy through glutathione synthesis
    Leng Han, Lingjun Meng, Jiao Liu, Yangchun Xie, Rui Kang, Daniel J. Klionsky, Daolin Tang, Yuanyuan Jia, Enyong Dai · 2024 · Cancer Letters
96. Tumor-Infiltrating Immune Cell Signature Predicts the Prognosis and Chemosensitivity of Patients With Pancreatic Ductal Adenocarcinoma
    Yuzhen Gao, Shipeng Chen, Somayeh Vafaei, Xiaoli Zhong · 2020 · Frontiers in Oncology
97. Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases
    Camila Bragança Xavier, Katia Regina Marchetti, Tiago Biachi De Castria, Denis L. Fontes Jardim, Gustavo dos Santos Fernandes · 2020 · Journal of Gastrointestinal Cancer
98. Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer
    Manoj Amrutkar, Ivar P. Gladhaug · 2021 · Cancers
99. Elevated expression of RIT1 hyperactivates RAS/MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor
    Liang-Zhan Sun, Shaoyan Xi, Zhengdong Zhou, Feifei Zhang, Pengchao Hu, Yuzhu Cui, Shasha Wu, Ying Wang, Shayi Wu, Yanchen Wang et al. · 2021 · Oncogene
100. Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma
     Álvaro Gómez‐Tomás, José A. Pumarega, Juan Alguacil, André F.S. Amaral, Núria Malats, Natàlia Pallarés, Magda Gasull, Miquel S. Porta, for the PANKRAS II Study Group · 2019 · Environmental and Molecular Mutagenesis